Repligen to Report Initial Results of Phase 2 Clinical Trial Conference Call
and Web Cast Invitation
NEEDHAM, Mass., April 3 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN - news) announced today that the Company President and Chief Executive
Officer Dr. Walter C. Herlihy will host a conference call on Wednesday April 4, 2001 to report the initial results of the Phase 2 Clinical Trial of Secretin in Autism.
Please access the call at 8:55 a.m. EST on Wednesday April 4, 2001 via the internet at vcall.com or via the
Repligen web site at www.repligen.com. If you are unable to access the webcast via the internet, you can also listen to the broadcast by calling 1-800-289-0462.
To listen to the webcast via the internet, please go to the web site at least fifteen minutes early to register, download, and if necessary install Real Player audio
software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call on the Company's web site at www.repligen.com for 90
days.
Repligen Corporation develops new drugs for debilitating pediatric disorders including autism, cancer, and immune and metabolic disorders. Repligen also
manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. Its
corporate headquarters are located at 117 Fourth Avenue, Needham MA, 02494. Additional information may be requested from www.repligen.com. |
